Takeda

London – October 16, 2026 -- The global ADHD drugs market will grow from USD 14.11 billion in 2025 to USD 22.79 billion by 2035, a compound annual growth rate of 4.91%, according to Credence Research Inc. The figures are the research firm's proprietary estimates, not audited sales totals.

North America holds 60% of value while Asia Pacific grows fastest at 6.34%

North America accounted for 60.0% of 2025 market value. Europe followed with 20.0%, Asia Pacific with 13.0%, Latin America with 4.0% and the Middle East and Africa with 3.0%.

Credence attributes Asia Pacific's 6.34% annual growth to better recognition and access in Japan, Australia and, increasingly, China, from a comparatively small revenue base. In Europe, reimbursement systems and lower net medicine prices restrain value per patient.

Suzhou, China – September 24, 2026 -- Innovent Biologics (HKEX: 01801) will present late-breaking Phase 3 data for its CLDN18.2-targeting antibody-drug conjugate IBI343/TAK-921 at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, running October 23-27.

Phase 3 gastric cancer trial secures late-breaking oral slot

Results from the registrational G-HOPE-001 study, comparing Arcotatug Tavetecan against treatment of physician's choice in previously treated advanced gastric or gastroesophageal junction adenocarcinoma, will be delivered as a late-breaking abstract (LBA77) during the October 23 proffered paper session. Dr. Kohei Shitara of Chiba, Japan, will present the first interim analysis of the randomized, open-label trial.

Cambridge, Massachusetts – September 10, 2026 -- Insilico Medicine has published data in Nature Biotechnology showing that its AI-designed idiopathic pulmonary fibrosis (IPF) candidate rentosertib reversed predicted biological age by up to six years in some patients, based on six independently developed proteomic aging clocks.